The shadow of generic competition has long loomed over copyright’s iconic drug, Sildenafil, raising questions about the prospects of connected medicinal ventures. While initial years saw significant gains, the patent end has opened the way for less expensive alternatives, likely reducing earnings and creating a real danger for shareholders seekin